-
Daratumumab, sold
under the
brand name
Darzalex among others, is an anti-cancer
monoclonal antibody medication. It
binds to CD38,
which is overexpressed...
-
Daratumumab/hyaluronidase, sold
under the
brand name
Darzalex Faspro, is a fixed-dose
combination medication for the
treatment of
adults with
newly diagnosed...
- cyclophosphamide,
bortezomib and
dexamethasone (CyBorD) with
daratumumab added.
Daratumumab, a
monoclonal antibody to CD38, a
protein that is expressed...
-
vitro during trastuzumab treatment.
Multiple myeloma can be
treated with
daratumumab (Darzalex)
monoclonal antibody.
Studies with in
vitro materials and patient...
-
marker in leukemia.
Daratumumab (Darzalex)
which targets CD38 has been used in
treating multiple myeloma. The use of
Daratumumab can
interfere with pre-blood...
-
cancer (Seagen)
Marketed by partners:
Darzalex (IV) (
daratumumab) /
Darzalex Faspro (SC) (
daratumumab and hyaluronidase) for the
treatment of all stages...
-
groupings include one or more of a
monoclonal antibody (e.g.,
isatuximab or
daratumumab), an
immunomodulatory agent (e.g.,
lenalidomide or pomalidomide), and...
-
symptoms of the
TEMPI syndrome was
reported with the
drugs bortezomib,
daratumumab and
autologous stem cell transplantation. In 2010, the case of a man...
-
daratumumab is in the
recognition of the
different amino acid groups.
Isatuximab identifies 23
amino acids of CD38 to the
contrary with
daratumumab who...
- (Rituxan Hycela), trastuzumab/hyaluronidase-oysk (Herceptin Hylecta),
daratumumab/hyaluronidase-fihj (Darzalex Faspro), pertuzumab/trastuzumab/hyaluronidase–zzxf...
